News | May 14, 2024
Bayer Q1 2024 net income drops 8.2% to € 2 billion
EBITDA before special items falls 1.3 percent to € 4.41 billion
EBITDA before special items falls 1.3 percent to € 4.41 billion
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Subscribe To Our Newsletter & Stay Updated
